New York, NY– Metalmark Capital (“Metalmark”), a leading private equity firm, announced that it has sold Collagen Matrix, Inc., (“Collagen Matrix”or the “Company”),a global developer and manufacturer of collagen and mineral-based medical devices. Financial terms of the transaction were not disclosed.

Founded in 1997and headquartered in New Jersey, Collagen Matrix is a leading developer and manufacturer of collagen and mineral-based products for tissue repair and regeneration. Leveraging strong product development and internal R&D capabilities, including two state-of-the-art manufacturing facilities, the Company has developed a propriety portfolio of collagen and non-collagen tissue engineering technologies that support the body’s natural ability to heal. Collagen Matrix’s products are suitable across a range of applications, including the growing device sectors of Dental, Neurosurgery, Orthopedics, Spine and Sports Medicine.

“We are proud to have partnered with the strong Collagen Matrix team during a time of considerable success for the Company,” said Howard Hoff en,Chairman and Chief Executive Officer of Metalmark. “Through numerous strategic investments since Metalmark’s investment in late 2014, Collagen Matrix has significantly strengthened its position in the marketplace. We are pleased to have supported Collagen Matrix’s sustained growth and wish the Company continued success as a trusted partner to medical device companies worldwide.

”“I’d like to thank the entire Metalmark team for their incredible collaboration,” said Bart Doedens, CEO of Collagen Matrix.“Under Metalmark’s stewardship, we have scaled our platform by expanding our product suite with innovative solutions spanning multiple clinical focus areas.Collagen Matrix is well positioned to further its proven track record as an innovation leader, delivering high-quality collagen and mineral based products for the diverse needs of our customers.”

Financial and Legal Advisors Robert W. Baird & Co.and Piper Jaffray & Co.acted as financial advisors and Ropes & Gray LLP acted as legal advisor to Collagen Matrix on the transaction.

About Metalmark Capital

Metalmark Capital is a leading private equity firm that seeks to build long-term value through active and collaborative partnerships with business owners, founders, and executives. The firm focuses its investment activity in healthcare, industrials and agribusiness. Metalmark Capital manages funds with $3.7 billion in aggregate capital commitments.

For more information: http://www.metalmarkcapital.com

About Collagen Matrix

Collagen Matrix, Inc., founded in 1997, delivers a full line of the highest-quality collagen and mineral based medical devices that support the body’s natural ability to regenerate. The Company currently manufactures finished medical devices in the areas of Dental, Spine, Orthopedic, Dural Repair and Nerve Repair Surgery. The evolution of the Company’s leadership, proprietary technologies, manufacturing expertise and product portfolio has established a solid foundation for continued growth. Opportunities continue to exist for collaboration through Product Distribution, Product Development and Contract Manufacturing.

More information about Collagen Matrix can be found at www.Collagen Matrix.com.

Media Contacts:

Sard Verbinnen & Co.

Warren Rizzi

Phone: +1 (212) 687-8080

EQT Credit, through its Direct Lending investment strategy, is pleased to announce its support for Alanta Health Group (“Alanta” or the “Company”) with EUR 331 million of committed senior facilities. Proceeds were used to refinance the Company’s existing debt as well as provide committed acquisition facilities to support its future growth

Owned by IK Investment Partners since 2016, Alanta is one of the largest certified compounders for patient-individualized infusions, which are applied mainly in oncology treatment in Germany.

Ralph Betz, Managing Director at EQT Partners and Investment Advisor to EQT Credit, commented: “Alanta is the leading German player in compounding and distribution of infusions for oncology treatments. We were particularly attracted by the Company’s high-quality offering and the management team’s impressive track record in developing a vertically-integrated business model. We would like to thank EQT’s Industrial Advisors, who added their knowledge of the pharmaceutical industry to provide key support and insight throughout the due diligence process. This transaction consolidates the long-standing relationship between IK Investment Partners and EQT Credit”

Paul Johnson, Partner at EQT Partners and Investment Advisor to EQT Credit, added: “Alanta’s market-leading position provides it with a strong opportunity to further consolidate the industry. We look forward to supporting Alanta and its management team in their continued growth and expansion.”

Contact
Paul Johnson, Partner at EQT Partners, Investment Advisor to EQT Credit
Ralph Betz, Managing Director at EQT Partners, Investment Advisor to EQT Credit
EQT Press Office, +46 8 506 55 334, press@eqtpartners.com

About EQT
EQT is a leading investment firm with more than EUR 61 billion in raised capital across 29 funds and around EUR 40 billion in assets under management. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtpartners.com

About EQT Credit
EQT Credit invests through three complementary strategies: Senior Debt, Direct Lending, and Special Situations. Since inception, EQT Credit has raised over EUR 7 billion of capital and invested in over 160 companies. EQT Credit’s Direct Lending strategy seeks to provide flexible, long-term debt solutions to support European businesses, across a wide range of sectors. These businesses include privately-owned companies seeking growth capital as well as those that are the subject of private equity-led acquisitions or refinancings

For more information: www.eqtpartners.com/business-segments/Credit

• EQT to partner with founder and CEO Michael Chambers, as well as TA Associates, to support Aldevron on its future growth journey
• EQT will support Aldevron through investments in additional production capacity, R&D, and growth initiatives and by leveraging EQT’s strong healthcare expertise, global presence, and network of Industrial Advisors

The EQT VIII Fund (“EQT” or “EQT VIII”) today announced that it has entered into an agreement to acquire a majority interest in Aldevron (the “Company”). Following the close of the transaction, EQT VIII will own a majority interest in the Company. Founders, management and TA Associates will retain a minority stake.

Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is the leading global supplier of GMP, GMP-SourceTM and Research Grade plasmid DNA used in commercial, clinical and research stage gene therapies, as well as proteins, antibodies and mRNA. The Company’s custom development and manufacturing capabilities enable scientists worldwide to develop groundbreaking new therapies with a focus on quality, speed and innovation. Aldevron is based in Fargo, North Dakota and has additional operations in Madison, Wisconsin and Freiburg, Germany. The Company employs approximately 400 people worldwide and serves more than 4,800 clients, including leading academic and research institutions, pharmaceutical and biotechnology companies.

EQT will help advance Aldevron’s R&D and innovation efforts as the Company continues to

support the rapidly growing field of genetic medicine by providing a critical input for the development of new life-saving therapies. EQT will also support Aldevron with investments in additional production capacity at its Fargo campus, furthering the Company’s position as a key employer in North Dakota.

Michael Chambers, Co-Founder and CEO of Aldevron, commented: “We’re very proud of what Aldevron has accomplished over the past two decades. We remain committed to our clients and their work, and to our mission – to develop and manufacture biologics at the highest quality that help make meaningful changes, worldwide. EQT shares our strong values and commitment to excellence and we believe their significant healthcare experience, global presence and industrial network make them an ideal partner as we continue our growth journey.”

Eric Liu, Partner at EQT Partners and Investment Advisor to EQT VIII, said: “EQT has followed the life science tools and gene therapy market closely for many years, and we believe Aldevron is uniquely positioned as a critical supplier to this rapidly growing market. The Company helps its clients deliver leading edge therapies that address previously uncurable medical conditions and improve patient lives around the world. Aldevron has unparalleled scientific-know how, scale and process expertise, enabling the Company to deliver the highest quality products. We are excited to partner with Michael and his team to further develop Aldevron and invest in the Fargo community in these exciting times.”

Marc Wolff, CFO of Aldevron, said: “EQT is among the top 10 private equity investors in the world. They bring considerable financial strength and international reach to Aldevron. With EQT’s strategic approach, TA Associates’ experience with us, and their collective ability to provide informed, industry guidance, we will be in an excellent position for continued growth, which will further bolster our commitment to our clients, their work and the patients they serve.”

Ethan Liebermann, Director at TA Associates, said: “We have been pleased with our partnership with Michael and the Aldevron team and are looking forward to continuing this journey with our new partners at EQT.”

Mark Carter, Managing Director at TA Associates, added: “EQT is one of the most respected firms in private equity and we are eager to embark on a new chapter together at Aldevron.”

Morten Hummelmose, Chairman of EQT Partners Inc. and Head of EQT Equity US, said: “This transaction represents another important milestone for EQT in the US. EQT VIII has now invested in US businesses within each of our three core sectors, Healthcare, TMT and Business Services, and we are excited to continue EQT’s successful track record of developing companies across these industries.”

The transaction is expected to close by year-end, subject to regulatory conditions and approvals.

Morgan Stanley & Co. LLC acted as financial advisor to EQT, and Simpson Thacher & Bartlett LLP provided legal counsel. Goldman Sachs acted as financial advisor to TA Associates, and Kirkland & Ellis LLP provided legal counsel.

Contact
Eric Liu, Partner at EQT Partners and Investment Advisor to EQT VIII, +1 917 281 0850
US inquiries: Stephanie Greengarten, +1 646 687 6810, stephanie.greengarten@eqtpartners.com
International inquiries: EQT Press Office, +46 8 506 55 334, press@eqtpartners.com

About EQT
EQT is a leading investment firm with more than EUR 61 billion in raised capital across 29 funds and around EUR 40 billion in assets under management. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com

About TA Associates
TA Associates is one of the most experienced global growth private equity firms. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $32.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $2 billion per year. The firm’s more than 85 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com.

About Aldevron
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron is known for inventing the GMP-SourceTM quality system, and for specializing in GMP manufacturing, operating the world’s largest facility at its company headquarters in Fargo, North Dakota. Aldevron has additional facilities in Madison, Wisconsin, and Freiburg, Germany.More info: www.aldevron.com

25/07/2019 – 08:00 | Portfolio

Combined Entity Brings Complementary Resources and Expertise to Support Critical Interoperability Initiatives Including FHIR®, Cloud Transformation and National Data Exchange Networks

BOSTON, Massachusetts – July 10, 2019 – Rhapsody, a global leader in healthcare data interoperability, today announced that the company will merge with Corepoint Health, the supplier of the Best in KLAS® healthcare integration platform. The transaction will bring together two companies at the forefront of interoperability and create a dynamic combination of technology, talent, services, and trusted customer relationships to address the most complex healthcare interoperability challenges.

Both companies will continue to support and advance their respective solutions, while the combined entity will also devote its expanded resources to addressing the growing need for interoperability among regional, national and international healthcare providers and vendors.

“Corepoint’s platform offers incredibly fast, turn-key operations for provider organizations, HIEs and OEM partners, all with industry leading customer satisfaction. Complementing this with Rhapsody’s fully customizable and multi-platform capabilities creates great synergies for our current and future customers,” said Erkan Akyuz, President and CEO, Rhapsody. “Both entities share great technical depth and breadth and both have maintained long-standing customer relationships, which together yields a broader foundation on which to build the future of interoperability in healthcare. Together, we can better support our customers to fulfill all of their changing and future needs.”

Available on premises and as a cloud-based service, the Rhapsody and Corepoint interoperability platforms offer comprehensive routing and transformation functionality for every operating environment, offering highly differentiated features, applications and end customer focuses. The two platforms also support commonly used messaging standards and protocols such as FHIR®, HL7® V2, CCD/C-CDA and DICOM. These integration engines are among the most secure technology platforms in the healthcare industry, with customer bases that include the entire healthcare ecosystem and across the globe, including provider organizations, technology vendors, HIEs and public health systems.

“We are entering a new era in healthcare where the emphasis will be on expanding ecosystems and establishing new data trading partner relationships to optimize clinical and operational workflows. These initiatives will be powered by interoperability and data management: healthcare organizations that can excel in these areas will have a significant competitive advantage,” said Sean Cassidy, CEO of Corepoint Health. “The combination of Rhapsody and Corepoint enables our customers to continue to get tremendous value out of the products and services they love, while having the confidence that their interoperability partner is heavily invested in helping them confront the challenges they will face in the future.”

“We move decisively when perfect opportunities present themselves,” said Philippe Houssiau, Operating Partner at Hg. “The opportunity to bring Corepoint and Rhapsody together was incredibly compelling. Our investments in these two phenomenal companies demonstrate how excited we are about the future of interoperability. Rhapsody is off to an amazing start as an independent company: joining forces with Corepoint will enable the combined team to accelerate the delivery of FHIR-based services, cloud-based integration solutions and support for regional and national interoperability frameworks.”

Learn more here.

About Corepoint 

Corepoint Health delivers a powerful yet simplified approach to internal and external health data integration and exchange for hospitals, radiology centers, laboratories, and clinics. Our software solutions help health care providers and vendors achieve their interoperability goals. For the 10thconsecutive year, Corepoint Integration Engine has earned the #1 ranking in the Best in KLAS Awards: Software & Services report. To learn more about Corepoint Health, visit https://corepointhealth.com

About Hg

Hg is a specialist private equity investor, committed to building businesses that change the way we all do business, through deep sector specialization and dedicated operational support. We are a leading European investor in software and services businesses, with increasing global presence, having built a team of 170 people over 25 years. Hg partners with the businesses and management teams we invest in, sharing best-practice ‘playbooks’ and leveraging Hg’s executive and portfolio network as a powerful tool for knowledge sharing across comparable businesses. Based in London, Munich and New York, Hg has funds under management of around $13 billion serving some of the world’s leading institutional and private investors. For further details, please see www.hgcapital.com

Media Contacts: